Molecular Formula | C25H30N8OS |
Molar Mass | 490.62 |
Density | 1.325±0.06 g/cm3(Predicted) |
Appearance | Yellowish-white powder |
pKa | 12.82±0.40(Predicted) |
Storage Condition | -20C |
In vitro study | PF-3758309 was a potent (Kd = 2.7 nM),ATP competitive PAK4 inhibitor with a Ki of 18.7 nM. In cells, PF-3758309 inhibited the phosphorylation of PAK4 matrix GEF-H1 (IC50=1.3 nM) and the Anchorage-independent growth of tumor cell lines (IC50=4.7 nM). PF-3758309 also inhibited the accumulation of endogenous pGEF-H1 in HCT116 cells. PF-3758309 can effectively inhibit the differentiation (IC50=20 nM) and Anchorage Independent growth (IC50=27 nM) of A549 cells. PF-3758309 is a potent (K d = 2.7 nM) ATP competitive PAK4 inhibitor with K I of 18.7 nM. In cells, PF-3758309 inhibited the phosphorylation of PAK4 matrix GEF-H1 (IC50=1.3 nM) and the Anchorage-independent growth of tumor cell lines (IC50=4.7 nM). PF-3758309 also inhibited the accumulation of endogenous pGEF-H1 in HCT116 cells. PF-3758309 can effectively inhibit the differentiation (IC50=20 nM) and Anchorage Independent growth (IC50=27 nM) of A549 cells. |
In vivo study | PF-3758309 blocking the growth of a variety of human tumor xenografts, the plasma EC50 value was 0.4 nM in most sensitive models. In the HCT116 tumor model, PF-3758309 was able to resist proliferation and induce apoptosis. PF-3758309 blocked the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in most sensitive models. In the HCT116 tumor model, PF-3758309 was able to resist proliferation and induce apoptosis. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.038 ml | 10.191 ml | 20.382 ml |
5 mM | 0.408 ml | 2.038 ml | 4.076 ml |
10 mM | 0.204 ml | 1.019 ml | 2.038 ml |
5 mM | 0.041 ml | 0.204 ml | 0.408 ml |